A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2021-11-03
250
Participants Needed
22
Research Sites
N/A
Total Duration
On this page
AI-Summary
Official Title
Who Can Participate
Trial Site Locations
How is the study designed?
Frequently Asked Questions
Research Publications
Sponsors
N
National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor
S
Schering-Plough
Collaborating Sponsor
AI-Summary
What this Trial Is About
To determine the impact of dose intensity on tumor response and survival in patients with HIV-associated non-Hodgkin's lymphoma (NHL).
HIV-infected patients are at increased risk for developing intermediate and high-grade NHL. While combination chemotherapy for aggressive B-cell NHL in the absence of immunodeficiency is highly effective, the outcome of therapy for patients with AIDS-associated NHL has been disappointing. Treatment is frequently complicated by the occurrence of multiple opportunistic infections, as well as the presence of poor bone marrow reserve, making the administration of standard doses of chemotherapy difficult. A recent study was completed using a low-dose modification of the standard mBACOD (cyclophosphamide, doxorubicin, vincristine, bleomycin, dexamethasone, methotrexate ) treatment. A 46 percent response rate was observed in patients treated with this combination of chemotherapeutic agents, with a number of durable remissions and reduced toxicity when compared to previous experience with more standard treatments. A subsequent study showed similar effectiveness using a lower dose of methotrexate administered on day 15. It is hoped that the use of sargramostim (granulocyte-macrophage colony-stimulating factor; GM-CSF) will improve bone marrow function and allow for administration of a higher dose of chemotherapy.
CONDITIONS
Official Title
A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma
Who Can Participate
Age: 12Years +
All Genders
Eligibility Criteria
You may qualify if you...
Inclusion Criteria
Concurrent Medication:
Required:
PCP prophylaxis with Bactrim, aerosolized pentamidine, or dapsone.
Allowed:
ddI, except when patient is also taking allopurinol.
Patients must have the following:
Diagnosis of HIV seropositivity and non-Hodgkin's lymphoma.
Ability to give informed consent and willingness to comply with all procedures and visit schedule.
If between ages of 12 and 18 must receive care under direct supervision of a pediatric oncologist, and have consent of parent, guardian, or person with power of attorney.
Participation in clinical trials of other antiretroviral agents is at the discretion of the investigator and individual patient.
Exclusion Criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Active opportunistic infection, excluding Mycobacterium avium complex, requiring antibiotic therapy.
Another prior or current malignancy, excepting curatively treated cervical or basal cell carcinoma.
Kaposi's sarcoma if rapidly progressive, with visceral involvement, or causing peripheral edema.
Primary central nervous system lymphoma.
Concurrent Medication:
Excluded:
Zidovudine (AZT) or any antiretroviral agent unless allowed by investigator. ddI is allowed except when also taking allopurinol.
Systemic myelosuppressive drugs, including trimethoprim/sulfamethoxazole (T/S), pyrimethamine/sulfa, or ganciclovir.
-
Patients with the following are excluded:
Active opportunistic infection, excluding Mycobacterium avium complex, requiring antibiotic therapy.
Another prior or current malignancy, excepting curatively treated cervical or basal cell carcinoma.
Kaposi's sarcoma if rapidly progressive, with visceral involvement, or causing peripheral edema.
Primary central nervous system lymphoma.
Prior Medication:
Excluded:
Immunomodulating agents within 2 weeks of study entry.
Prior Treatment:
Excluded:
Chemotherapy.
Radiation therapy as outlined in protocol.
You will not qualify if you...
History of severe allergic reactions to study medication
Currently pregnant or breastfeeding
Recent participation in another clinical trial within the last 30 days
Presence of uncontrolled medical conditions that could affect safety
Trial Site Locations
Total: 22 locations
1
USC CRS
Los Angeles, California, United States, 900331079
Status Unknown
2
UCLA CARE Center CRS
Los Angeles, California, United States, 90095
Status Unknown
3
Ucsf Aids Crs
San Francisco, California, United States, 941102859
Status Unknown
4
University of Colorado Hospital CRS
Aurora, Colorado, United States, 80262
Status Unknown
5
Northwestern University CRS
Chicago, Illinois, United States, 60611
Status Unknown
6
Rush Univ. Med. Ctr. ACTG CRS
Chicago, Illinois, United States, 60612
Status Unknown
7
Indiana Univ. School of Medicine, Infectious Disease Research Clinic
Indianapolis, Indiana, United States, 462025250
Status Unknown
8
Johns Hopkins Adult AIDS CRS
Baltimore, Maryland, United States
Status Unknown
9
Beth Israel Deaconess Med. Ctr., ACTG CRS
Boston, Massachusetts, United States, 02118
Status Unknown
10
Beth Israel Deaconess - East Campus A0102 CRS
Boston, Massachusetts, United States, 02215
Status Unknown
11
Bmc Actg Crs
Boston, Massachusetts, United States
Status Unknown
12
Washington U CRS
St Louis, Missouri, United States
Status Unknown
13
SUNY - Buffalo, Erie County Medical Ctr.
Buffalo, New York, United States, 14215
Status Unknown
14
Beth Israel Med. Ctr. (Mt. Sinai)
New York, New York, United States, 02215
Status Unknown
15
NY Univ. HIV/AIDS CRS
New York, New York, United States, 10016
Status Unknown
16
Memorial Sloan-Kettering Cancer Ctr.
New York, New York, United States, 10021
Status Unknown
17
Univ. of Rochester ACTG CRS
Rochester, New York, United States, 14642
Status Unknown
18
Unc Aids Crs
Chapel Hill, North Carolina, United States, 275997215
Status Unknown
19
Case CRS
Cleveland, Ohio, United States
Status Unknown
20
The Ohio State Univ. AIDS CRS
Columbus, Ohio, United States, 432101228
Status Unknown
21
Hosp. of the Univ. of Pennsylvania CRS
Philadelphia, Pennsylvania, United States, 19104
Status Unknown
22
Pitt CRS
Pittsburgh, Pennsylvania, United States, 15213
Status Unknown
Loading map...
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
N/A
Model
N/A
Primary Purpose
TREATMENT
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: analysis of AIDS Clinical Trials Group protocol 142--low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases.